<DOC>
	<DOCNO>NCT00894179</DOCNO>
	<brief_summary>Purpose : The investigator plan test newly FDA approve pharmacologic stress agent , Regadenoson , conjunction atropine use stress echocardiography diagnosis coronary artery disease . The selective nature Regadenoson allow use patient contraindication currently use drug , Adenosine , non-selective . Furthermore , propose protocol complete faster without radiation exposure current protocol adenosine . Design : This prospective study evaluate people prior diagnosis coronary disease prior stress test schedule cardiac catheterization . Patients meet inclusion criterion undergo regadenoson-atropine echocardiography protocol prior catheterization . The study interpret two independent reader blind catheterization result . The sensitivity , specificity , positive negative predictive value regadenoson-atropine study calculate use coronary angiogram gold standard .</brief_summary>
	<brief_title>Safety Accuracy Study Regadenoson Atropine Combination Stress Echocardiography Identification Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<criteria>1 . Age &gt; 18 year old 2 . Able provide consent 3 . Scheduled cardiac catheterization either without prior functional stress image study 1 . Any history acute myocardial infarction , prior PCI last 3 month , bypass surgery , 2 . History great first degree AV block , sick sinus syndrome patient 3 . Patients pacemaker/LBBB 4 . History uncontrolled arrhythmias 5 . Patients significant pulmonary disease , know suspect bronchoconstrictive bronchospastic lung disease hypersensitivity adenosine 6 . History cardiac transplantation , hypertrophic cardiomyopathy , acute myocarditis pericarditis , severe valvular heart disease 7 . Hemodynamically unstable patient 8 . Dipyridamole use within 30 hour , consumption methylxanthines ( e.g. , tea , coffee , caffeinated soft drink , chocolate , cocoa ) within 12 hour , use sublingual nitroglycerin within 2 hour 9 . History glaucoma obstructive uropathy 10 . Allergy hypersensitivity atropine 11 . Participation another investigational drug study within 1 month participation previous regadenoson trial 12 . Pregnancy , breast feeding , use acceptable method birth control ( premenopausal ) 13. . History endstage renal disease hemodialysis peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>stress echocardiography</keyword>
	<keyword>regadenoson</keyword>
	<keyword>atropine</keyword>
	<keyword>coronary angiogram</keyword>
</DOC>